Home › Compare › ACUS vs NNN

ACUS vs NNN: Dividend Comparison 2026

ACUS yields 20000000.00% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACUS wins by $4.875981653489057e+49M in total portfolio value
10 years
ACUS
ACUS
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full ACUS calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — ACUS vs NNN

📍 ACUS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACUSNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACUS + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ACUS pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACUS
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, ACUS beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACUS + NNN for your $10,000?

ACUS: 50%NNN: 50%
100% NNN50/50100% ACUS
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

ACUS
No analyst data
Altman Z
-30.0
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACUS buys
0
NNN buys
0
No recent congressional trades found for ACUS or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACUSNNN
Forward yield20000000.00% ✓5.68%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$4.875981653489057e+49M$25.6K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$2,637.42
Total dividends collected$4.875978515990276e+49M$13.7K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ACUS vs NNN ($10,000, DRIP)

YearACUS PortfolioACUS Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$10,737$617.02+$2000.00M → ACUS
2$373,835,915,712,384$373,833,775,700,934.50$11,577$710.93+$373835915.70M → ACUS
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$12,538$822.59+$65304953364964.95M → ACUS
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$13,645$956.06+$10661728832755499008.00M → ACUS
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$14,925$1,116.51+$1.626767783781495e+24M → ACUS
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$16,415$1,310.57+$2.319743300546251e+29M → ACUS
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$18,158$1,546.77+$3.0915106403922057e+34M → ACUS
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$20,213$1,836.20+$3.8505079858392777e+39M → ACUS
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$22,649$2,193.37+$4.4821026103531426e+44M → ACUS
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$25,558$2,637.42+$4.875981653489057e+49M → ACUS

ACUS vs NNN: Complete Analysis 2026

ACUS — Stock

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Full ACUS Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this ACUS vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACUS vs SCHDACUS vs JEPIACUS vs OACUS vs KOACUS vs MAINACUS vs ADCACUS vs EPRTACUS vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.